TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers

TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers

ABSTRACT: TNG908 is a clinical stage PRMT5 inhibitor with an MTA-cooperative binding mechanism designed to leverage the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion. MTAP deletion occurs in 10–15 % of all human cancer representing multiple histologies. MTA is a negative re...

Full description

Saved in:
Bibliographic Details
Main Authors: Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Alice Tsai, Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, Steven A. Lombardo, Satoshi Yoda, Erik W. Wilker, Samuel R. Meier, Yi Yu, Teng Teng, Alan Huang, John P. Maxwell
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Translational Oncology
Subjects:
PRMT5
MTAP
MTA-cooperative
synthetic lethality
collateral lethality
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324003905
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items